--- title: "Top Penny Stocks To Watch In June 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/288460965.md" description: "Simply Wall St highlights Baozun, Butler National, and Elite Pharmaceuticals as top penny stocks for June 2026. Despite market volatility, these companies demonstrate strong financial health, including positive cash flow, debt coverage, and profitability improvements. The article emphasizes fundamental analysis for identifying growth opportunities in smaller-cap firms." datetime: "2026-06-02T17:15:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288460965.md) - [en](https://longbridge.com/en/news/288460965.md) - [zh-HK](https://longbridge.com/zh-HK/news/288460965.md) --- # Top Penny Stocks To Watch In June 2026 The market has shown positive momentum, with a 1.6% increase over the last week and a 28% climb in the past year, while earnings are projected to grow significantly in the coming years. In this context, identifying stocks with strong financial health is crucial for navigating potential growth opportunities. Penny stocks—though an older term—still represent viable options for investors seeking to tap into smaller or newer companies that might offer substantial returns when backed by solid fundamentals. Let's take a closer look at a couple of our picks from the screened companies. ## Baozun (BZUN) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Baozun Inc. provides end-to-end e-commerce solutions in China and has a market cap of approximately $150.55 million. **Operations:** The company generates revenue through its E-Commerce segment, which accounts for CN¥8.45 billion, and its Brand Management segment, contributing CN¥1.99 billion. **Market Cap:** $150.55M Baozun Inc., with a market cap of US$150.55 million, is currently unprofitable but shows potential due to its strong cash position exceeding total debt and a positive free cash flow, providing a runway of over three years. Recent earnings reports indicate an improvement in net loss from CN¥63.08 million to CN¥7.46 million year-over-year for Q1 2026, alongside revenue growth to CN¥2.38 billion from CN¥2.06 billion the previous year. Despite challenges such as negative return on equity and increasing losses over five years, Baozun trades at significant value below estimated fair value and maintains seasoned management and board teams. - Jump into the full analysis health report here for a deeper understanding of Baozun. - Review our growth performance report to gain insights into Baozun's future. ## Butler National (BUKS) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Butler National Corporation operates in the aerospace industry by designing, engineering, manufacturing, and servicing a range of aerostructures and aircraft components, with a market cap of $267.25 million. **Operations:** The company's revenue is primarily derived from its Gaming segment, which generated $37.45 million, followed by Aircraft Modifications at $32.45 million, Special Mission Electronics with $17.26 million, and Aircraft Avionics contributing $4.74 million. **Market Cap:** $267.25M Butler National Corporation, with a market cap of US$267.25 million, demonstrates strong financial health as its operating cash flow covers 75.7% of its debt and EBIT covers interest payments 22.9 times over. The company’s short-term assets of US$66.4 million exceed both short-term and long-term liabilities, reinforcing its solid balance sheet position. Recent earnings for Q3 2026 show revenue growth to US$26.91 million from US$21.17 million a year ago, with net income rising to US$6.7 million from US$3.38 million the previous year, highlighting robust profitability improvements alongside a share buyback initiative enhancing shareholder value. - Unlock comprehensive insights into our analysis of Butler National stock in this financial health report. - Explore historical data to track Butler National's performance over time in our past results report. ## Elite Pharmaceuticals (ELTP) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $370.50 million. **Operations:** The company's revenue primarily comes from its Abbreviated New Drug Applications (ANDA) segment, generating $140.12 million. **Market Cap:** $370.5M Elite Pharmaceuticals, Inc., with a market cap of US$370.50 million, has shown financial resilience by becoming profitable this year and maintaining stable weekly volatility. Its seasoned management team and board contribute to strategic stability, while the company's short-term assets of US$96.8 million comfortably cover both short-term (US$13.2 million) and long-term liabilities (US$32.9 million). Elite's recent launch of generic methadone tablets taps into a market with annual retail sales of approximately US$22 million in 2025, potentially enhancing revenue streams. The company is trading significantly below estimated fair value and has reduced its debt-to-equity ratio over five years from 26.7% to 3.8%. - Navigate through the intricacies of Elite Pharmaceuticals with our comprehensive balance sheet health report here. - Gain insights into Elite Pharmaceuticals' past trends and performance with our report on the company's historical track record. ## Make It Happen - Unlock more gems! Our US Penny Stocks screener has unearthed 328 more companies for you to explore.Click here to unveil our expertly curated list of 331 US Penny Stocks. - Contemplating Other Strategies? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [BZUN.US](https://longbridge.com/en/quote/BZUN.US.md) - [09991.HK](https://longbridge.com/en/quote/09991.HK.md) ## Related News & Research - [Baozun (NASDAQ:BZUN) CEO Acquires $26,500.00 in Stock](https://longbridge.com/en/news/289180676.md) - [Baozun (NASDAQ:BZUN) CEO Acquires $27,700.00 in Stock](https://longbridge.com/en/news/289180622.md) - [Embraer hails growing jet backlog, sees main E2 engine issues solved](https://longbridge.com/en/news/289475294.md) - [Vietnam orders airlines to fast-track US aircraft deals amid trade probes](https://longbridge.com/en/news/289181890.md) - [Bombardier takes off with $100m Seletar service expansion](https://longbridge.com/en/news/289267137.md)